FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Kintz Samuel</u>						2. Issuer Name and Ticker or Trading Symbol Enliven Therapeutics, Inc. [ELVN]								ck all application			10% Ov	ner	
(Last) (First) (Middle) C/O ENLIVEN THERAPEUTICS, INC. 6200 LOOKOUT ROAD						3. Date of Earliest Transaction (Month/Day/Year) 02/23/2023)	X Officer (give title Other (specify below) President and CEO					
(Street)	ER C	0	80301		4.	If Am	endment, [Date o	of Original Filed (Month/Day/Year)				Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(8	State)	(Zip)	- Davis		0		- ^ -		Die		of av Da		. 0					
1. Title of Security (Instr. 3) 2. Trans: Date (Month/L				action	Execution Date,		3. Transaction Code (Instr.		4. Securit	ies Acquire		5. Amount Securities Beneficial Owned Fo	ly	Form:	Direct Ir Indirect B tr. 4) C	7. Nature of Indirect Beneficial Ownership			
					,		Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 ar	on(s)		(1	nstr. 4)			
Common Stock		02/23	3/2023				A		1,087,5	,087,525 A		1,087,525				ee ootnote ⁽²⁾			
Common Stock		02/23	2/23/2023				A		88,53	1 A	(1)	88,531				dee ootnote ⁽³⁾			
Common Stock			02/23	02/23/2023				A		88,53	1 A	(1)	88,5	,531			bee bootnote ⁽⁴⁾		
			Table II -								osed of converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day)	Date, T	I. Fransaction Code (Instr.		Derivative I		6. Date Exercisa Expiration Date (Month/Day/Yea		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficie Owned Followin Reported Transact	re es ally ig d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)		Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Employee Stock Option (right to buy)	\$1.12	02/23/2023			A		344,550		(5)		06/15/2030	Common Stock	344,550	(6)	344,5	550	D		
Employee Stock Option (right to	\$2.48	02/23/2023			Α		404,363		(7)		03/24/2031	Common Stock	404,363	(6)	404,3	363	D		

Explanation of Responses:

buy)

- 1. Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."
- 2. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
- 3. The shares held of record by an irrevocable trust dated October 26, 2021 for the benefit of Mr. Kintz's elder son and for which Mr. Kintz serves as an investment advisor.
- 4. The shares held of record by an irrevocable trust dated October 26, 2021 for the benefit of Mr. Kintz's younger son and for which Mr. Kintz serves as an investment advisor
- 5. The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.
- 6. In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)
- 7. The shares subject to the option vest in 48 equal monthly installments beginning on January 14, 2021.

Remarks:

/s/ Ben Hohl, by power of 02/27/2023 <u>attorney</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.